Happy New Year!
Low Incidence of Blood Clots Found in U.S. Transgender Women on Hormone Therapy
All of us at the ISSM would like to wish you and your families a very happy, healthy, and prosperous new year!
- Prof. Luca Incrocci, ISSM President, and the ISSM Board of Directors
Venous thromboembolism (VTE) - blood clots - are uncommon in transgender women undergoing cross-sex hormone therapy in the United States, researchers have found.
The study, recently published in the Journal of Sexual Medicine, focused specifically on hormone preparations used in the U.S., which are different from those used in Europe.
VTE has been a concern for individuals transitioning from male to female. Clots may form in the legs or break off and travel to the lungs. Much of the research on VTEs in this population has concentrated on the European protocols.
For this study, scientists examined the medical charts of 676 transgender women undergoing cross-sex hormone therapy in the U.S. between 2008 and 2016. The participants were on therapy for an average of 1.9 years.
Only one patient experienced a VTE during this period, resulting in a rate of 0.15%.
Future studies that compare the U.S. and European approaches directly are needed to determine which combinations are the safest and most effective, the authors said.
Click here for more details.